To characterize effects on protein synthesis, we performed polysome and ribosome profiling (Ribo-seq).<h4>Results</h4>We show that targeting the Ras-MAPK pathway using clinically approved MEK1/2 inhibitors induces AXIN1 loss across a panel of CRC cell lines and patient-derived organoids. Here, MAP2K1 is linked to colorectal carcinoma.